AbbVie's Rova-T Disappoints As Second-Line SCLC Trial Halted

 
• By John Davis

Enrolment In the Phase III TAHOE study has been halted due to shorter overall survival in the Rova-T arm compared with the control arm.  

Golfer
The results of the TAHOE study are disappointing • Source: Shutterstock

More from Anticancer

More from Therapy Areas